Li Lai: The large-scale head-to-head study showed that Telbopaptide has a cardiovascular protective effect.

On July 31st, Lilly announced the results of the SURPASS-CVOT phase 3 study. This first head-to-head comparison of two incretin-based therapies for cardiovascular outcomes included adult patients with type 2 diabetes and atherosclerotic cardiovascular disease. In this study, the GIP/GLP-1 receptor agonist tirzepatide was compared with the GLP-1 receptor agonist dulaglutide, which has been previously shown to have cardiovascular protective effects in the REWIND study. The SURPASS-CVOT study met its primary endpoint, with tirzepatide being non-inferior to dulaglutide in terms of the risk of major adverse cardiovascular events. Additionally, tirzepatide showed improvements in A1C, weight, kidney function, and all-cause mortality.